biopharmaceuticals - транскрипция, произношение и перевод онлайн

Транскрипция и произношение слова "biopharmaceuticals" в британском и американском вариантах. Подробный перевод и примеры.

biopharmaceuticals / биофармацевтических
[ˌbaɪəʊˌfɑːməˈsuːtɪkəlz]
[ˌbaɪəʊˌfɑːməˈsuːtɪkəlz]
Перевод
прилагательное
биофармацевтический
biopharmaceutical
Определения
имя существительное
a biological macromolecule or cellular component, such as a blood product, used as a pharmaceutical.
The second area where we have enormous strength is in our core technical competencies, which enable us to conduct effective product development in pharmaceuticals, biopharmaceuticals , and devices.
Примеры
The second area where we have enormous strength is in our core technical competencies, which enable us to conduct effective product development in pharmaceuticals, biopharmaceuticals , and devices.
In positioning itself for the decade ahead, the IDA has targeted the biotechnology sector in particular, as pharmaceutical companies begin to switch the manufacturing process from chemicals to biopharmaceuticals .
Well, lucky for them they got there first because the commercial application of using cells for factories so that hormones and proteins could produce biopharmaceuticals wasn't lost on the business world.
‘The future of biopharmaceuticals has simply never been brighter,’ said Laos.
These new GM crops, known as biopharmaceuticals , or biopharms for short, produce industrial and pharmaceutical chemicals within their tissues.
Whether such biopharmaceuticals will be regulated under the protocol remains to be seen, says Dawkins: ‘That was still far enough into the future that it wasn't addressed directly.
Volunteer corn in both locations contained traces of unidentified biopharmaceuticals from 2001 field trials.
As for particular sectors and industries, the life sciences - biopharmaceuticals and medical devices are getting most of the buzz right now and at least some of the money.
He is most concerned about biopharmaceuticals as a major problem for the future.
A couple of examples from my own experience at FDA with the review of biopharmaceuticals will illustrate the tension between the regulatory culture and innovation.